TCGA-44-6146-01A-11R-1755-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 64
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.470
- TGF_BETA_SIGNALING+0.470
- UV_RESPONSE_DN+0.380
- ANDROGEN_RESPONSE+0.340
- ESTROGEN_RESPONSE_EARLY+0.320
- ADIPOGENESIS+0.290
- NOTCH_SIGNALING+0.230
- BILE_ACID_METABOLISM+0.220
- HEME_METABOLISM+0.220
- PI3K_AKT_MTOR_SIGNALING+0.210
Top 10 suppressed
- E2F_TARGETS-0.600
- MYC_TARGETS_V2-0.550
- MYC_TARGETS_V1-0.480
- G2M_CHECKPOINT-0.470
- ALLOGRAFT_REJECTION-0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- SPERMATOGENESIS-0.290
- MTORC1_SIGNALING-0.270
- ANGIOGENESIS-0.230
- INTERFERON_GAMMA_RESPONSE-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-44-6146-01A-11R-A278-07 | — | cohortA1 | 0.877 |
| 2 | TCGA-97-7547-01A-11R-2039-07 | — | cohortA1 | 0.851 |
| 3 | TCGA-75-6206-01A-11R-1755-07 | — | cohortA2 | 0.829 |
| 4 | ULC0569T_S27 | — | cohortA1 | 0.823 |
| 5 | C3N-00959 | — | cohortA1 | 0.805 |
| 6 | TCGA-OR-A5LL-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.797 |
| 7 | SRR23036899 | — | — | 0.793 |
| 8 | SRR8518290 | — | F | 0.793 |
| 9 | MNG1049 | — | — | 0.783 |
| 10 | SRR12475121 | — | — | 0.778 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.470 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.470 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.380 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.340 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.320 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.290 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.220 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.210 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.160 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.130 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.120 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.110 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.110 | Inavolisib | — uncovered |